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STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 Item 
No Recommendation 
(a) Indicate the study’s design with a commonly used term in the title or the abstract  Title and abstract 1 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
(a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Participants 6 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
(a) Describe all statistical methods, including those used to control for confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) If applicable, explain how loss to follow-up was addressed 
Statistical methods 12 
(e) Describe any sensitivity analyses 
Results 
(a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
Participants 13* 
(c) Consider use of a flow diagram 
(a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of interest 
Descriptive data 14* 
(c) Summarise follow-up time (eg, average and total amount) 
Outcome data 15* Report numbers of outcome events or summary measures over time 
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
Main results 16 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
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Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
 
